Valuation: Shenzhen YHLO Biotech Co., Ltd.

Capitalization 8.23B 1.21B 1.02B 941M 891M 1.65B 112B 1.68B 11.03B 4.32B 54.18B 4.53B 4.44B 191B P/E ratio 2025
355x
P/E ratio 2026 * 23.5x
Enterprise value 8.23B 1.21B 1.02B 941M 891M 1.65B 112B 1.68B 11.03B 4.32B 54.18B 4.53B 4.44B 191B EV / Sales 2025
-
EV / Sales 2026 * 3.38x
Free-Float
42.44%
Yield 2025 *
0.69%
Yield 2026 * 2.08%
1 day-1.64%
1 week-2.96%
Current month-1.44%
1 month-5.63%
3 months-4.88%
6 months+0.49%
Current year+1.48%
1 week 14.4
Extreme 14.4
15.02
1 month 14.21
Extreme 14.21
15.27
Current year 13.51
Extreme 13.51
17
1 year 13.51
Extreme 13.51
17
3 years 13.51
Extreme 13.51
28.27
5 years 13.51
Extreme 13.51
52.71
10 years 13.51
Extreme 13.51
52.71
Manager TitleAgeSince
Chief Executive Officer 42 30/11/2012
Director of Finance/CFO 47 21/12/2022
Chief Tech/Sci/R&D Officer 44 30/09/2015
Director TitleAgeSince
Chairman 35 31/12/2017
Chairman 42 30/11/2012
Director/Board Member 51 27/06/2019
Change 5d. change 1-year change 3-years change Capi.($)
-1.64%-2.96%-3.42%-24.32% 1.23B
+0.20%+0.72%+19.75%+22.13% 13.03B
+0.06%+0.04%+17.25%-7.19% 9.31B
-2.16%-1.05%+62.04%+45.36% 5.96B
+1.49%+6.23%+5.02%-21.12% 5.95B
-0.46%-1.71%-15.71%+54.21% 5.3B
-0.39%+0.61%-3.42%+4.83% 4.82B
+3.00%+3.74% - - 3.94B
-0.65%-3.43%+16.77%-49.53% 1.78B
-1.29%-1.54%+58.66%+7.84% 1.49B
Average -0.18%+0.61%+17.44%+3.58% 5.28B
Weighted average by Cap. +0.03%+0.95%+17.00%+11.67%

Financials

2025 2026 *
Net sales 1.98B 291M 246M 226M 214M 397M 26.88B 404M 2.65B 1.04B 13.03B 1.09B 1.07B 45.93B 2.44B 357M 303M 278M 264M 488M 33.06B 497M 3.26B 1.28B 16.02B 1.34B 1.31B 56.48B
Net income 221M 32.36M 27.41M 25.22M 23.87M 44.24M 2.99B 45.02M 295M 116M 1.45B 121M 119M 5.12B 381M 55.85M 47.31M 43.53M 41.2M 76.36M 5.17B 77.7M 510M 200M 2.51B 210M 205M 8.83B
Net Debt - -
Logo Shenzhen YHLO Biotech Co., Ltd.
Shenzhen YHLO Biotech Co Ltd is a China-based company principally engaged in the research and development, manufacture and sales of in-vitro diagnostic equipment and supporting reagents, as well as the agency sales of some non-self-produced medical device products. The Company's products are applied in autoimmunity, reproductive health, diabetes and infectious disease fields. The Company's main products include in-vitro diagnostic instruments and supporting reagents based on chemiluminescence, immunoblotting, enzyme-linked immunoassay, immunofluorescence chromatography and other methodologies. The Company distributes its products in domestic market and to overseas markets.
Employees
1,678
Date Price Change Volume
17/04/26 14.41 ¥ -1.64% 4,053,748
16/04/26 14.65 ¥ -2.33% 6,466,264
15/04/26 15.00 ¥ +1.49% 6,748,178
14/04/26 14.78 ¥ -0.34% 4,250,426
13/04/26 14.83 ¥ -0.13% 4,666,638
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.41CNY
Average target price
17.65CNY
Spread / Average Target
+22.46%

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688575 Stock